Highlights
- Sun Pharmaceutical Industries will acquire all outstanding shares of Organon at $14.00 per share in an all-cash deal valued at $11.75 billion.
- The transaction represents the largest deal ever struck by an Indian biopharmaceutical company.
- Organon's biosimilars business is expected to make Sun Pharma the world's seventh-biggest biosimilar company.
- The deal has been approved by both companies' boards and is expected to close in early 2027, pending regulatory and shareholder approvals.
Sun Pharmaceutical Industries (NSE:SUNPHARMA), India's largest drugmaker, has agreed to acquire US-listed Organon & Co. in an all-cash transaction valued at $11.75 billion on an enterprise basis, marking the largest deal ever undertaken by an Indian biopharmaceutical company. Under the terms of the agreement, Sun Pharma will pay $14.00 per share for all outstanding shares of Organon.
The acquisition represents a transformative step for Sun Pharma's global ambitions, positioning the company to enter the ranks of the world's top 25 pharmaceutical companies by revenue.
Why Investors Are Watching
The deal's scale and strategic rationale have made it one of the most closely watched developments in Indian pharma this year. Organon, spun off from Merck in 2021 and known as MSD outside the United States and Canada, specialises in women's health and biosimilars, with more than 70 products sold across 140 countries.
The acquisition is expected to grant Sun Pharma access to Organon's biosimilars portfolio, positioning the combined entity as the world's seventh-biggest biosimilar company, a significant strategic upgrade for Sun Pharma's global product mix.
Market Context
The transaction, valued at a roughly 60% premium to Organon's closing price before news of takeover interest first emerged, was struck against the backdrop of a broader surge in India's outbound M&A activity in 2026. Sun Pharma's deal alone was the single largest contributor to India's outbound acquisition value, which rose more than sixfold in Q2 2026 compared with Q1.
Sun Pharma plans to fund the acquisition through a combination of internal cash resources and committed bank financing, with post-transaction net debt-to-EBITDA projected at 2.3 times, reflecting a measured approach to leverage for a deal of this scale.
What Market Participants Will Monitor
Market participants will track the progress of regulatory approvals and the Organon shareholder vote required to complete the transaction, which is expected to close in early 2027. The integration of Organon's biosimilars and women's health portfolios into Sun Pharma's existing global operations will also be a key area of focus once the deal closes.
Sun Pharma's post-deal leverage profile and its ability to manage the projected net debt-to-EBITDA ratio of 2.3 times will also be relevant for assessing the financial impact of the transaction on the combined entity.
Industry or Peer Perspective
The deal elevates Sun Pharma's standing among global pharmaceutical companies and will invite comparisons with other large Indian pharmaceutical players expanding internationally, including through their own generics, specialty, and biosimilars strategies. Within India's listed pharma sector, other companies such as Lupin have also been active in expanding their international regulatory approvals and product pipelines, reflecting a broader trend of Indian pharma companies scaling their global footprint.
The transaction also stands out within India's 2026 M&A landscape as the single largest outbound deal, reinforcing the growing role Indian pharmaceutical companies are playing in global healthcare consolidation.
Conclusion
Sun Pharmaceutical Industries' $11.75 billion acquisition of Organon marks a landmark moment for Indian pharma, both as the largest deal in the sector's history and as a strategic move that could reshape the company's global positioning in biosimilars and women's health. With the transaction expected to close in early 2027, its integration and financing execution will be closely watched in the coming quarters.
FAQs
Q: Why is the company in focus today?
A: Sun Pharmaceutical Industries (NSE:SUNPHARMA) is in focus after agreeing to acquire US-listed Organon & Co. for $11.75 billion, the largest deal ever undertaken by an Indian biopharmaceutical company.
Q: What factors are investors monitoring?
A: Investors are monitoring the progress of regulatory and shareholder approvals, the planned closing in early 2027, the integration of Organon's biosimilars portfolio, and Sun Pharma's post-deal leverage profile.
Q: Which peer companies are relevant?
A: Lupin (NSE:LUPIN) is a relevant peer among Indian pharmaceutical companies expanding their global regulatory approvals and international product pipelines.
Q: Is this article investment advice?
A: No. This article is intended solely for informational purposes and should not be considered investment, financial or trading advice.